{"editorial":{"content_id":"1352bf99-f2e8-4592-bd42-9be18f40468d","slug":"anvisa-20261026-5a8140","content_type":"news","title":"巴西Anvisa将于10月29日召开2026年第20次公开例会","summary":"巴西国家卫生监督局（Anvisa）董事会将于10月29日上午9时30分召开2026年第20次公开例行会议。","body":"巴西国家卫生监督局（Anvisa）董事会（Dicol）将于本周四（10月29日）上午9时30分召开2026年第20次公开例行会议。\n\n据Anvisa发布的信息，会议议程全文以及处于审议阶段的提案草案均已可查询。\n\n会议地点为巴西利亚（DF）Anvisa总部内的Dicol会议室。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-10-26T17:01:03.534Z","display_date":"2026-10-26","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/acompanhe-a-20a-reuniao-ordinaria-publica-da-diretoria-colegiada-da-anvisa","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":["regulatory_uncertainty","compliance_risk"],"opportunity_flags":[],"trend_signals":[]},"intelligence":{"intel_id":"f49826ad-66e4-4433-a8f1-c6bb34ceacdd","version":1,"event_type":"监管表态","event_date":"2026-10-29","main_entities":[{"name":"巴西国家卫生监督局（Anvisa）","role":"召开公开例会的监管机构","type":"regulator","country":"巴西","normalized_name":null},{"name":"Anvisa董事会（Dicol）","role":"会议主体，负责审议监管提案","type":"government_body","country":"巴西","normalized_name":null},{"name":"巴西利亚Anvisa总部Dicol会议室","role":"会议地点","type":"location","country":"巴西","normalized_name":null}],"main_action":"Anvisa董事会将于2026年10月29日召开第20次公开例会","key_numbers":[{"unit":"次","label":"会议次数","value":"20"},{"unit":"时","label":"开始时间","value":"09:30"}],"facts":[{"verified":false,"statement":"Anvisa董事会（Dicol）将于2026年10月29日上午9时30分召开2026年第20次公开例行会议。","source_excerpt":null},{"verified":false,"statement":"会议议程全文以及处于审议阶段的提案草案均已可查询。","source_excerpt":null},{"verified":false,"statement":"会议地点为巴西利亚Anvisa总部内的Dicol会议室。","source_excerpt":null}],"assessments":[{"statement":"公开议程和草案可查询，有助于企业提前跟踪Anvisa监管动向。","confidence":"high","basis_fact_index":null},{"statement":"会议可能涉及处于审议阶段的提案，但未披露具体内容，监管影响尚不确定。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"user","priority":"normal","description":"跟进会议议程和提案草案，评估对药品、医疗器械、化妆品等健康产品注册合规的影响。"}],"affected_audience":["在巴西运营的医药企业","医疗器械企业","化妆品及健康产品企业","合规与注册事务团队","关注巴西卫生监管的投资者"],"risk_flags":["regulatory_uncertainty","compliance_risk"],"opportunity_flags":[],"trend_signals":[],"follow_up_needed":true,"follow_up_questions":["会议议程中具体审议哪些提案？","草案是否涉及药品、医疗器械或化妆品注册规则变化？","会议是否形成决议或后续公开征求意见安排？"],"related_topics":["Anvisa","Dicol","公开例会","监管议程","卫生监督","巴西"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-26T17:01:19.523Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-20261026-5a8140","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261026-5a8140","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261026-5a8140?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261026-5a8140?view=json","last_updated":"2026-10-26T17:01:20.336Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}